PH12021551949A1 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
PH12021551949A1
PH12021551949A1 PH1/2021/551949A PH12021551949A PH12021551949A1 PH 12021551949 A1 PH12021551949 A1 PH 12021551949A1 PH 12021551949 A PH12021551949 A PH 12021551949A PH 12021551949 A1 PH12021551949 A1 PH 12021551949A1
Authority
PH
Philippines
Prior art keywords
cancer treatment
cancer
treatment
erdafitinib
provides
Prior art date
Application number
PH1/2021/551949A
Other languages
English (en)
Inventor
Anjali Narayan Avadhani
Porre Peter Marie Z De
Anne Elizabeth O`Hagan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PH12021551949A1 publication Critical patent/PH12021551949A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH1/2021/551949A 2019-02-12 2020-02-11 Cancer treatment PH12021551949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19176575 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Publications (1)

Publication Number Publication Date
PH12021551949A1 true PH12021551949A1 (en) 2022-07-18

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/551949A PH12021551949A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Country Status (16)

Country Link
US (1) US20220168298A1 (enExample)
EP (1) EP3923942A1 (enExample)
JP (2) JP2022521173A (enExample)
KR (1) KR20210126654A (enExample)
CN (1) CN113423402A (enExample)
AU (1) AU2020223467B2 (enExample)
BR (1) BR112021015686A2 (enExample)
CA (1) CA3126959A1 (enExample)
IL (1) IL285466A (enExample)
JO (1) JOP20210216A1 (enExample)
MA (1) MA54932A (enExample)
MX (1) MX2021009670A (enExample)
PH (1) PH12021551949A1 (enExample)
SG (1) SG11202107850VA (enExample)
TW (1) TWI863962B (enExample)
WO (1) WO2020165181A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
KR20230152652A (ko) * 2020-12-11 2023-11-03 에라스카, 아이엔씨. 암 치료를 위한 병용 요법
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
AU2020223467B2 (en) 2025-12-04
TW202045173A (zh) 2020-12-16
US20220168298A1 (en) 2022-06-02
CN113423402A (zh) 2021-09-21
TWI863962B (zh) 2024-12-01
MA54932A (fr) 2021-12-22
JP2022521173A (ja) 2022-04-06
AU2020223467A1 (en) 2021-08-05
EP3923942A1 (en) 2021-12-22
KR20210126654A (ko) 2021-10-20
JP2026016402A (ja) 2026-02-03
SG11202107850VA (en) 2021-08-30
CA3126959A1 (en) 2020-08-20
BR112021015686A2 (pt) 2021-10-26
IL285466A (en) 2021-09-30
WO2020165181A1 (en) 2020-08-20
MX2021009670A (es) 2021-09-08
JOP20210216A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
CA193736S (en) Skin massager
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
TN2019000211A1 (en) Antitumoral compounds
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
MX2022008868A (es) Tratamiento del cancer con tg02.
GB201903546D0 (en) Cancer treatment
ZA202206743B (en) Therapy for the treatment of cancer
EA201991818A1 (ru) Лечение рака
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2021009670A (es) Tratamiento para el cancer.
IL281439A (en) Combined treatment for blood cancer
TW201613587A (en) Medical treatments based on anamorelin
MX2020008195A (es) Compuestos para el tratamiento del dolor.
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL287652A (en) Cancer treatment
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
IL284162A (en) Integrated healing for cancer treatment
IL305780A (en) Cancer treatment methods
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007665A (es) Terapia de combinacion para tratar o prevenir el cancer.
IL288035A (en) Cancer treatment
EA202192163A1 (ru) Лечение рака